Direct factor Xa inhibitors in atrial fibrillation: advantages and new treatment options
AbstractThe article presents a review of studies for 2018–2024 on the benefits of using direct factor Xa inhibitors in atrial fibrillation in comparison with other drugs that prevent thrombotic complications.
The aim of the study was to describe the advantages and new possibilities of therapy with direct factor Xa inhibitors in atrial fibrillation.
The objectives were to compare the effectiveness and safety of the use of direct factor Xa inhibitors, vitamin K antagonists (using the example of warfarin) and antiplatelet agents; to highlight the possibility of using alternative anticoagulants dosages for atrial fibrillation; to present a modern publications analysis on promising representatives of the group of direct Xa factor inhibitors (edoxaban, rivaroxaban).
Results. Based on the analysis of publications, it was concluded that the use of direct Xa factor inhibitors in atrial fibrillation is significantly effective and safe, especially in groups of patients with concomitant diseases (diabetes mellitus, chronic kidney disease).
Keywords:atrial fibrillation; prevention of thrombotic complications; direct anticoagulants; edoxaban; rivaroxaban; warfarin
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Minenok V.A., Sautkin E.P., Stepchenko M.A., Meshcherina N.S. Direct factor Xa inhibitors in atrial fibrillation: advantages and new treatment options. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2024; 12 (1): 30–5. DOI: https://doi.org/10.33029/2309-1908-2024-12-1-30-35 (in Russian)
References
1. Getman S.I. Characteristics of Disturbances of Heart Rhythm and Conduction Among Patients Attending Consultation of a Cardiologist at Ambulatory Stage. Kardiologiya [Cardiology]. 2018; 58 (6): 20–8. (in Russian)
2. Hammett C., Badve S.V., Kerr P.G., et al. Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice. Heart, Lung and Circulation. 2022; 31 (12): 1604–11.
3. Karpov Yu.A. New possibilities of anticoagulant therapy in patients with atrial fibrillation. Atmosfera. Novosti cardiologii [Atmosphere. Cardiology news]. 2023; 2: 3–12. (in Russian)
4. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2022; 42 (5): 373–498.
5. NHFA CSANZ Atrial Fibrillation Guideline Working Group; Brieger D., Amerena J., Attia J., Bajorek B., Chan K.H., et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018; 27 (10): 1209–66.
6. Di Lullo, Tripepi G., Ronco C., et al. Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2019; 278: 243–9.
7. Sønderskov P.S., Lindholt J.S., Hallas J., et al. Association of aortic valve calcification and vitamin K antagonist treatment. Eur Heart J Cardiovasc Imaging. 2020; 21: 718–24.
8. Posch F., Ay C., Stoger H., Kreutz R., Beyer-Westendorf J. Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. Res Pract Thromb Haemost. 2019; 3: 207–16.
9. Coleman C.I., Kreutz R., Sood N., et al. Rivaroxaban’s impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan claims database analysis. Clin Appl Thrombo Hemost. 2019; 25: Article 1076029619868535.
10. González Pérez A., Balabanova Y., Sáez M.E., Brobert G., García Rodríguez L.A. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: a population-based study from the United Kingdom. Int J Cardiol. 2022; 352: 165–71.
11. Hernandez A.V., G. Bradley, Khan M., et al. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes. Eur Heart J Qual Care Clin Outcomes. 2020; 6: 301–7.
12. Shahzada T.S., Guo C.L., Lee A.P.W. Renal outcomes in Asian patients receiving oral anticoagulants for non-valvular atrial fibrillation. Hong Kong Med J. 2020; 28: 24–32.
13. Dai L., Schurgers L.J., Shiels P.G., Stenvinkel P. Early vascular ageing in chronic kidney disease: impact of inflammation, vitamin K, senescence and genomic damage. Nephrol Dial Transplant. 2020; 35: ii31-ii37.
14. Petzold T., Thienel M., Dannenberg L., et al. Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1. Circ Res. 2020; 126: 486–500.
15. Kreutz R., Deray G., Floege J., Gwechenberger M., et al. Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. JACC: Advances. 2024; 3 (2): 100813.
16. Steffel J., Collins R., Antz M., et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021; 23 (10): 1612–76.
17. Casula M., Fortuni F., Fabris F., Leonardi S., Gnecchi M., Sanzo A., Greco A., Rordorf R. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis. J Cardiovasc Med (Hagerstown). 2020; (8): 570–6.
18. Kanorskiy S.G. Anticoagulant therapy for patients with atrial fibrillationin in special situations: diabetes mellitus and/or chronic kidney disease. Kardiologiya [Cardiology]. 2018; 58 (7S): 4–10. (in Russian)
19. Modi A.D., Pancholi Y.N., Modi D.M. Comparing monopharmacotherapy of antiarrhythmic and anticoagulant drugs with other drugs for atrial fibrillation: A complete review of clinical trials. Medicine in Drug Discovery. 2023; 18: 100154.
20. Corsini A., Ferri N., Proietti M., Boriani G. Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs Jul. 2020; 80 (11): 1065–83.
21. Pharmaceuticals and Medical Devices Agency. Japanese package insert for Edoxaban. Accessed June 8, 2022. URL: https://www.info.pmda.go.jp/go/pack/3339002F1020_1_14
22. Cervantes C.E., Merino J.L., Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019; 17 (4): 319–30.
23. Akashi S., Oguri M., Ikeno E., et al. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial. JAMA Netw Open. 2022; 5 (8): e2228500.
24. Carlin S., Eikelboom J.W. Direct oral anticoagulant dose selection: challenging cases. J Thromb Haemost. 2021; 19: 2680–6.
25. Cho M.S., Yun J.E., Park J.J., et al. Pattern and impact of off-label underdosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation who are indicated for standard dosing. Am J Cardiol. 2020; 125: 1332–8.
26. Cheng K.H., Tu H.P., Cheng K.C., Scherrer-Crosbie M., Hsu T.Y. Cardiovascular and Neurological Outcomes in Patients Treated with Edoxaban for Atrial Fibrillation and Characteristics in Patients with Cancer. medRxiv [Preprint]. 2023; 2023:10.25.23297577.
27. Chao T.-F., Chan N.-Y., Chan Y.-H. et al. Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: An Asian Perspective. JACC: Asia. 2023; 3 (5): 707–23.
28. Gencer B., Eisen A., Berger D., et al. Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups. Am Heart J. 2022; 247: 24–32.
29. Zhang B., Cheng W., Kaisaier W., Gu Z., Zhu W., Jiang Q. Effect of edoxaban compared with other oral anticoagulants for stroke prevention in patients with atrial fibrillation: A meta-analysis. Heliyon. 2023; 9 (11): e21740.